New scan could better show how melanoma fights immunotherapy
NCT ID NCT07215182
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 30 times
Summary
This study is testing a special PET/CT scan using a tracer called [68Ga]Ga-FAPI-46 to see if it can better track how advanced melanoma responds to immunotherapy. About 20 adults with stage IV melanoma will get two of these scans—one before starting treatment and one after three months—plus blood samples and follow-up. The goal is to compare this new scan with standard imaging to improve how doctors evaluate treatment success.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT MELANOMA STAGE IV are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Herlev Universityhospital
RECRUITINGHerlev, Capital Region, 2730, Denmark
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Rigshospitalet
RECRUITINGCopenhagen, Ca, 2100, Denmark
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.